MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2024.102119

Медицинская библиотека · Clinical genitourinary cancer · 2024

Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy.

de Angelis Mario, Scheipner Lukas, Siech Carolin, Jannello Letizia Maria Ippolita, Baudo Andrea, Bello Francesco Di, Goyal Jordan A, Vitucci Kira, Tian Zhe, Longo Nicola, Ahyai Sascha, de Cobelli Ottavio, Chun Felix K H, Saad Fred, Shariat Shahrokh F, Carmignani Luca, Gandaglia Giorgio, Moschini Marco, Montorsi Francesco, Briganti Alberto, Karakiewicz Pierre I

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Trimodal therapy (TMT) is guideline-recommended for the management of organ confined urothelial carcinoma of urinary bladder (UCUB). However, temporal trends in TMT use and cancer-specific mortality free-survival (CSM-FS) between historical TMT versus contemporary TMT have not been assessed. We addressed this knowledge gap.

MATERIAL AND

METHODS

Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified nonmetastatic UCUB patients with cT2-T4aN0-N2 treated with TMT, defined as the combination of transurethral resection of bladder tumor, chemotherapy and radiotherapy. Temporal trends described TMT use over time. Subsequently, patients were divided between historical (2004-2012) versus contemporary (2013-2020) cohorts. Survival analyses consisting of Kaplan-Meier plots and multivariable Cox regression (MCR) models addressed CSM-FS. Separate analyses addressed patients with organ confined (OC: cT2N0M0) versus nonorgan confined (NOC: cT3-4a and/or cN1-2) clinical stages.

RESULTS

Of 4,097 assessable UCUB TMT patients, 1744 (43%) were treated in the historical period (2004-2012) versus 2353 (58%) in the contemporary period (2013-2020). TMT use increased over time in OC patients (EAPC:+3.4%, P < .001), as well as in NOC (EAPC:+2.7%, P < .001). In OC stage, median CSM-FS was 55.3% in historical versus 49.0% in contemporary patients (HR:0.75, P < .001). Similarly, in NOC stage, 5-year median CSM-FS was 43.0% in historical versus 32.8% in contemporary patients (HR:0.78, P = .01).

CONCLUSION

TMT rates have increased over time in both OC and NOC patients. Contemporary TMT patients benefit of better cancer-specific survival. Interestingly, this benefit applies equally to OC and NOC TMT-treated patients.

Для цитирования: de Angelis Mario, Scheipner Lukas, Siech Carolin, Jannello Letizia Maria Ippolita, Baudo Andrea, Bello Francesco Di, Goyal Jordan A, Vitucci Kira, Tian Zhe, Longo Nicola, Ahyai Sascha, de Cobelli Ottavio, Chun Felix K H, Saad Fred, Shariat Shahrokh F, Carmignani Luca, Gandaglia Giorgio, Moschini Marco, Montorsi Francesco, Briganti Alberto, Karakiewicz Pierre I. Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy.. Clinical genitourinary cancer. 2024. DOI: 10.1016/j.clgc.2024.102119.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.